Hasil Pencarian  ::  Simpan CSV :: Kembali

"buku ini membahas tentang buku ajar khusus ditulis untuk mahasiswa sastra inggris supaya mampu membaca kritis terhadap cerita pendek "

"Latar Belakang: Pandemi COVID-19 menyebabkan mortalitas dan morbiditas yang tinggi khususnya pada tenaga kesehatan di Indonesia, Studi mengenai manfaat dari vaksin booster mRNA-1273 yang diawali vaksinasi primer Coronavac masih minim sehingga diperlukan penelitian lebih lanjut.Tujuan: Penelitian ini dilakukan untuk mengetahui faktor yang berhubungan dengan insiden COVID-19 pasca vaksinasi booster mRNA-1273 yang diberikan vaksinasi primer Coronavac sebelumnya serta profil antibodi pada tenaga kesehatan di Indonesia.Metode: Penelitian ini menggunakan gabungan desain kohort retrospektif dan potong lintang pada 300 tenaga kesehatan yang dipilih secara acak dari data penerima vaksin booster mRNA-1273 di salah satu RS tersier (RSCM). Subjek yang terpilih kemudian dilakukan wawancara mendalam mengenai riwayat vaksinasi COVID-19, riwayat terinfeksi COVID-19, komorbiditas dan dilakukan pengambilan sampel darah untuk menilai kadar antibodi IgG sRBD. Dari hasil wawancara kemudian dinilai faktor-faktor yang berhubungan terhadap kejadian COVID-19 pasca vaksinasi booster mRNA-1273 serta profil antibodi subjek.Hasil: 56 orang (18,6%) mengalami COVID-19 setelah divaksinasi booster dalam 5 bulan. Incidence rate per person per month sebesar 3,2%. Median antibodi IgG sRBD dalam 8 bulan 6627 AU/ml (min-max, 729-20374 AU/ml) dan tidak berhubungan dengan variabel usia, jenis kelamin, komorbiditas, KIPI pasca booster ataupun riwayat infeksi pasca booster. Usia, jenis kelamin, diabetes melitus tipe 2, hipertensi, obesitas dan KIPI pasca booster tidak berhubungan terhadap insiden COVID-19 pasca booster. Riwayat COVID-19 sebelum vaksinasi booster berhubungan signifikan terhadap penurunan kejadian COVID-19 pasca vaksinasi booster dengan RR 0,20 (95 % CI: 0,09-0,45).Simpulan: Insiden COVID-19 mencapai 18,6% dalam 5 bulan pasca vaksinasi booster dengan riwayat COVID-19 sebelum vaksinasi booster berperan dalam menurunkan risiko kejadian COVID-19 pasca vaksinasi booster.

---

Background: COVID-19 pandemic has caused high mortality and morbidity especially among healthcare workers in Indonesia. Studies on the benefits of the mRNA-1273 booster vaccine preceded with Coronavac primary vaccine are still minimal so further studies are needed.

Purpose: Knowing the factors associated with the incidence rate of SARS-CoV-2 infection after mRNA-1273 booster vaccination starting with the Coronavac primary vaccination and the antibody profile of healthcare workers in Indonesia.

Method: This study used combined design of retrospective cohort and cross sectional study. Three hundreds healthcare workers at one of tertiary hospital in Indonesia that obtain mRNA-1273 booster vaccine minimal after 5 months were randomly selected. Subjects were then interviewed regarding their history of COVID-19 vaccination, history of SARS-CoV-2 infection, comorbidities and blood samples were taken to assess IgG sRBD antibody levels. Factors related to antibody profile and incidence of SARS-CoV-2 infection after the mRNA-1273 booster vaccination were then analyzed.

Results: 56 subjects (18.6%) experienced SARS-CoV-2 infection after mRNA-1273 booster vaccination. Median antibody IgG sRBD in 8 months was 6627 AU/ml (min-max, 729-20374 AU/ml) and not related to age, gender, comorbidities, AEFI after booster and infection after booster. Age, gender, diabetes type 2, hypertension, obesity, AEFI after booster were not related to COVID-19 incidence after booster. History of SARS-CoV-2 infection before booster vaccination was significantly associated with reduced risk of SARS-CoV-2 infection after booster vaccination with RR 0,20 (95 % CI: 0,09-0,45).

Conclusion: Cumulative incidence of SARS-CoV-2 infection in 5 months was 18,6% with history of COVID-19 before booster correlated with reduced risk of COVID-19 after booster."

"Latar Belakang: Indonesia menjalani program transisi pengobatan ARV pada ODHIV yang sudah stabil dengan terapi ARV berbasis nevirapine ke dolutegravir sejak 2023. Tujuan: Mengetahui perubahan kualitas hidup setelah 6 bulan menjalani transisi dari ARV zidovudine/ lamivudine/ nevirapine ke tenofovir/ lamivudine/ dolutegravir (TLD). Metode: Penelitian ini menggunakan desain kohort retrospektif terhadap 145 subjek yang menjalani program transisi. Kualitas hidup dinilai dengan kuisoner EQ-5D-3L versi bahasa Indonesia sebelum dan setelah 6 bulan menjalani transisi ARV ke TLD. Hasil: Dari 145 subjek penelitian, 83 (57,2%) subjek pria, median umur 43 (40 – 46,5) tahun dan 144 (99,3%) subjek dengan virus tidak terdeteksi. Median skor VAS EQ-5D-3L 90 (RIK 80 – 99) vs 90 (RIK 85 -100) (p <0,001) dan median skor utilitas EQ-5D-3L 1 (RIK 1 – 1) vs 1 (RIK 1 – 1) (p= 0,021). Simpulan: Ada perbaikan kualitas hidup berdasarkan skor VAS pasca menjalani program transisi antiretroviral meskipun dijumpai perburukan nyeri berdasarkan skor utilitas.

---

Background: Indonesia has a program to transition stable PLHIV from nevirapine-based ARV therapy to dolutegravir by 2023.

Objective: To determine the changes in quality of life after six months of transition from zidovudine/ lamivudine/ nevirapine to tenofovir/ lamivudine/ dolutegravir (TLD).

Methods: This study used a retrospective cohort design of 145 subjects undergoing the transition program. Quality of life was assessed with the Indonesian version of the EQ-5D-3L questionnaire before and after six months of transition.

Results: Of the 145 study subjects, 83 (57.2%) subjects were male, with a median age of 43 (40 - 46.5) years, and 144 (99.3%) subjects with the undetectable virus. The Median EQ-5D-3L VAS score was 90 (RIK 80 - 99) vs. 90 (RIK 85 -100) (p < 0.001), and the median EQ-5D-3L utility score were 1 (RIK 1 - 1) vs. 1 (RIK 1 - 1) (p = 0.021). There was no correlation between changes in weight, sleep quality, depression, and LFG and quality of life based on either utility or VAS scores.

Conclusion: There was an improvement in quality of life based on the VAS score after the antiretroviral transition program despite the worsening of pain based on the utility score."